Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease

Summary

This study evaluates the safety and tolerability of CDNF in patients with Parkinson's disease, when dosed directly into the brain using an implanted investigational drug delivery system (DDS). Safety and accuracy of the DDS is also being evaluated. One-third of the patients will receive monthly infusions with placebo and two-third of the patients will receive monthly infusions with either mid- or high-doses of CDNF for a period of 6 months.

Timeline

Start

2017-09-26

Primary completion

2019-12-19

Completion

2019-12-19

Publications

• Singh A, Panhelainen A, Reunanen S, Luk KC, Voutilainen MH. Combining fibril-induced alpha-synuclein aggregation and 6-hydroxydopamine in a mouse model of Parkinson's disease and the effect of cerebral dopamine neurotrophic factor on the induced neurodegeneration. Eur J Neurosci. 2024 Jan;59(1):132-153. doi: 10.1111/ejn.16196. Epub 2023 Dec 10.

Drugs

Indications